AstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing risk of disease progression or death by 69%.
The summer medical conference season is well and truly upon us and much of the focus this week is on the European League Against Rheumatism (EULAR) conference where several big pharma compa
AbbVie is the latest company to have an investigational drug for glioblastoma multiforme (GBM) – an aggressive form of brain cancer – fail at the final hurdle.
Roche and AbbVie’s Venclexta (venetoclax) has been approved by the FDA in combination with Roche’s Gazyva (obinutuzumab) for the treatment of people with previously untreated chronic lympho
Boehringer Ingelheim was the last man standing among challengers to AbbVie’s patents on immunology blockbuster Humira but has joined the pack and settled its litigation.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
